Warsaw-based Britenet Med has been awarded a €1 million grant from the European Institute of Innovation and Technology (EIT) Health to advance MoodMon, an AI-driven tool designed to improve the management and treatment of chronic affective disorders.
The funding was part of EIT Health’s notable Flagship Call, which supports groundbreaking healthcare innovations across Europe.
“Our mission with MoodMon is to transform the management of chronic affective disorders,” said Małgorzata Sochacka, MoodMon originator and Product Manager at Britenet Med. “By offering a first-in-class solution that leverages objective data for mental health monitoring, we aim to enhance patient outcomes, reduce healthcare costs, and enable professionals to allocate their time more effectively. The funding and collaboration opportunities provided by the EIT Health Flagship Call dedicated to the digital transformation of healthcare are crucial steps in bringing MoodMon to more patients and healthcare providers across Europe. But we don’t stop here . We are pleased to deepen our collaboration by joining EIT Health as a partner. We are confident that this will enable us to connect with additional exceptional partners across Europe, fostering the exchange of knowledge and expertise to enhance the treatment of mental illness on a global scale.”
Founded in 2006, Britenet is a Polish IT company specialising in consulting and outsourcing services, in relation to this they have developed the AI-based system MoodMon to support therapy for affective disorders.
MoodMon offers an innovative approach to monitoring conditions like depression and bipolar disorder, which impact an estimated 280 million people worldwide. Traditional monitoring methods rely on self-observation and subjective reporting, which often fall short in identifying subtle changes in mental states.
MoodMon leverages AI to analyse behavioural data collected via mobile devices and wearables, enabling real-time detection of mood changes. Its alert system notifies patients, psychiatrists, and caregivers promptly, enhancing treatment outcomes.
Clinical trials have demonstrated MoodMon’s accuracy, with a sensitivity rate of 89.5% and specificity of 98.83%.
The project is backed by a consortium of institutions across Europe, including Spain’s Fundació de Recerca Clínic Barcelona, Sweden’s Karolinska Institute, and Poland’s Medigent Foundation.
The consortium has been established to obtain CE certification, conducting further clinical trials, and exploring the economic benefits MoodMon offers to healthcare systems. The development team also aims to create regulatory frameworks that allow AI-driven devices like MoodMon to be updated without undergoing full recertification processes.
EIT Health’s Flagship Call, designed to address Europe’s most pressing healthcare challenges, highlights the importance of collaborative innovation.
“Our Flagship Calls are about catalysing collaborations that can make a real difference in European healthcare,” said Joanna Broy, EIT Health InnoStars Lead for Poland. “MoodMon is a prime example of what can be achieved when innovative companies like Britenet Med come together with leading institutions to address major health challenges. This project showcases the power of cross-border partnerships in developing solutions that are not only innovative but also scalable and impactful. We are excited to see how MoodMon will improve the lives of patients with affective disorders.”
In addition to improving patient care, MoodMon could significantly reduce healthcare costs. The annual direct cost of the depression treatment ranges from €3k to €5k per patient and the average direct cost of Bipolar Disorder treatment amounts to nearly €7k per year per patient.
MoodMon’s approach could alleviate these financial pressures by enabling early intervention and better disease management.
This funding also marks Britenet Med’s deeper integration into EIT Health’s network, positioning the company to collaborate with more European partners. As EIT Health has supported over 2,500 startups and brought 113 healthcare solutions to market, its role in advancing MoodMon is another step toward innovative solutions for managing mental health.
Read the orginal article: https://www.eu-startups.com/2024/12/meet-the-polish-startup-addressing-mental-health-with-their-moodmon-ai-tool/
